SOAT1 and familial pancreatic carcinoma: Additional proof of the influence of inflammation on immunotherapy is seen in its direct effect via JAK-STAT-mediated chronic inflammation, which hinders the activation of cytotoxic T lymphocytes and reduces the effectiveness of anti-PD-1 immunotherapy in pancreatic cancer.